Rocuronium Injectable Solution — Competitive Intelligence Brief

Rocuronium Injectable Solution (Rocuronium Injectable Solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-depolarizing neuromuscular blocking agent. Area: Anesthesia.

marketed Non-depolarizing neuromuscular blocking agent Nicotinic acetylcholine receptor Anesthesia Small molecule

Target snapshot

Rocuronium Injectable Solution (Rocuronium Injectable Solution) — Federal University of São Paulo. Rocuronium is a non-depolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at the nicotinic acetylcholine receptor on the motor endplate, causing muscle paralysis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Rocuronium Injectable Solution TARGET	Rocuronium Injectable Solution	Federal University of São Paulo	marketed	Non-depolarizing neuromuscular blocking agent	Nicotinic acetylcholine receptor
Succinylcholine Chloride	SUXAMETHONIUM	Novartis	marketed	Depolarizing Neuromuscular Blocker	Muscle-type nicotinic acetylcholine receptor	1952-01-01
Nicotine Mini-Lozenge for 11 Months	Nicotine Mini-Lozenge for 11 Months	University of Wisconsin, Madison	marketed	Nicotinic acetylcholine receptor agonist; Nicotine replacement therapy (NRT)	Nicotinic acetylcholine receptors
Extubation U	Extubation U	Seganest	marketed	Neuromuscular blocking agent	Nicotinic acetylcholine receptor
Rocuronium + sugammadex	Rocuronium + sugammadex	Brno University Hospital	marketed	Neuromuscular blocking agent (rocuronium) + selective relaxant binding agent (sugammadex)	Nicotinic acetylcholine receptor at the neuromuscular junction (rocuronium); rocuronium molecule itself (sugammadex)
Galantamine-CR	Galantamine-CR	Massachusetts General Hospital	marketed	Cholinesterase inhibitor with nicotinic receptor allosteric modulator	Acetylcholinesterase; nicotinic acetylcholine receptors
Succinylcholine + Neostigmine	Succinylcholine + Neostigmine	Brno University Hospital	marketed	Neuromuscular blocking agent reversal combination	Nicotinic acetylcholine receptor; acetylcholinesterase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-depolarizing neuromuscular blocking agent class)

1. University Hospital, Antwerp · 3 drugs in this class
2. Ain Shams University · 2 drugs in this class
3. Merck Sharp & Dohme LLC · 2 drugs in this class
4. Diskapi Yildirim Beyazit Education and Research Hospital · 1 drug in this class
5. Federal University of São Paulo · 1 drug in this class
6. Korea University Guro Hospital · 1 drug in this class
7. Assistance Publique Hopitaux De Marseille · 1 drug in this class
8. Ostfold Hospital Trust · 1 drug in this class
9. St. Antonius Hospital · 1 drug in this class
10. CHU de Reims · 1 drug in this class